Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells Authors: Bu Gyeom Kim, Bo Ram Kim, Dae Yeong Kim, Woo Young Kim, Sanghee Kang, Sun Il Lee, Sang Cheul Oh Published: 2024 ABSTRACT The anti–PD-L1 atezolizumab has limited efficacy in TNBC. The authors show that combining atezolizumab with cannabidiol enhances PD-L1 expression on PD-L1+ TNBC cells, improving T cell–mediated TNBC killing in vitro and TNBC control in syngeneic models. Introduction Triple-negative breast cancer (TNBC) accounts for approximately 15% to 20% of all breast cancer cases (1). It is characterized by the lack of expression of hormone receptors [estrogen receptor (ER) and progesterone receptor (PR)] and HER2. It is highly aggressive and has poor prognosis (2, 3). As a result, TNBC treatment still relies primarily on chemotherapy, as hormone therapy or HER2-targeted therapy would have limited effects owing to the lack of these receptors (4, 5). Despite adjuvant and neoadjuvant chemotherapy, individuals with advanced TNBC continue to have poor outcomes and high mortality rates (6). Moreover, a considerable proportion of patients do not respond to standard chemotherapy, which emphasizes the critical need for novel therapeutic options. Therefore, the development of efficient treatments for patients with TNBC is an urgent medical priority. Programmed cell death ligand 1 (PD-L1) is a crucial immune checkpoint molecule located on the surface of tumor cells. It interacts with its ligand, programmed cell death 1 (PD-1), on T cells (7). The interaction between PD-1 and PD-L1 prevents cytotoxic T-cell activation, causes T-cell exhaustion, and decreases the generation of cytotoxic cytokines, thereby reducing the immune response against cancer (8). Blockade of the PD-1/PD-L1 interaction can enhance the ability of T cells to exert anticancer effects (9). The use of monoclonal antibodies, known as immune checkpoint inhibitors (ICI), that can block the PD-1/PD-L1 interaction has revolutionized the treatment of several malignancies, including melanoma, lung cancer, Hodgkin lymphoma, bladder carcinoma, and renal cancer (10–14). Recent reports have shown that TNBC is the most immunogenic breast cancer subtype, with high levels of PD-L1 and a high number of tumor-infiltrating lymphocytes (TIL) in the tumor microenvironment (TME), making it an attractive candidate for ICI-based targeted treatment (15). Atezolizumab, an anti–PD-L1, has been approved as a first-line treatment for patients with PD-L1+, locally advanced, or metastatic TNBC in combination with nab-paclitaxel (16). Progression-free survival and overall survival of patients with PD-L1+ TNBC were improved by atezolizumab (17). Although atezolizumab has shown potential clinical benefits, only approximately 5% to 20% of patients with TNBC with PD-L1+ tumors respond to atezolizumab (18). This highlights the need for further research and development of more effective combination strategies to improve outcomes. Cannabidiol (CBD) is a nonpsychoactive compound found in cannabis. It has therapeutic benefits for neurodegenerative diseases, epilepsy, anxiety, and pain (19–22). It has been approved for the treatment of epilepsy by the FDA since 2018. CBD has been studied as a potential anticancer agent for several types of cancers, such as breast, lung, colon, prostate, and brain cancers (23–29). Previous studies have shown that CBD induces apoptotic cell death in colorectal cancer (30) and suppresses angiogenesis and stemness in breast cancer (31). In contrast to the psychoactive constituent tetrahydrocannabinol, CBD has low affinity for cannabinoid receptors CB1 and CB2 in cancer cells (32, 33). In addition, CBD acts as an immune modulator in the immune systems (34–37). Although a variety of findings from animal and clinical studies support the idea that CBD and cannabis promote immune-related responses (38–44), the underlying mechanism(s) of action remains unclear. The cyclic guanosine monophosphate-adenosine monophosphate synthase–stimulator of interferon genes (cGAS–STING) pathway is a major sensor of DNA damage in tumor cells and promotes anticancer immunity (45). STING activation can stimulate anticancer T cells by stimulating type I IFN–mediated inflammation (46). Therefore, the cGAS–STING pathway may be an effective way to enhance the effects of immunotherapy on tumors. In this study, we demonstrated a role for CBD as an immune modulator through PD-L1 upregulation in TNBC cells. CBD triggered cGAS–STING pathway activation and led to PD-L1 upregulation, thereby contributing to the enhanced efficacy of atezolizumab in TNBC cells. Additionally, CBD-induced PD-L1 upregulation potentiated the anticancer effect of anti–PD-L1 in syngeneic mouse models. These findings provide insights into the mechanisms underlying CBD-induced PD-L1 upregulation and suggest the potential for future development of new combination therapies for patients with PD-L1+ TNBC. Materials and Methods Cell culture All breast cancer cell lines were purchased from the ATCC in 2020. Human peripheral blood mononuclear cells (PBMC) were purchased from Stem Cell Technologies in 2021. MDA-MB-231 cells were cultured in DMEM medium (Gibco) containing 10% FBS (Gibco) and 100 mg/mL penicillin and streptomycin (GenDEPOT). BT20 cells were cultured in Eagle Minimum Essential Medium (ATCC) containing 10% FBS and 100 mg/mL penicillin and streptomycin. 4T1, EMT6, Jurkat T cells, and human PBMCs were cultured in RPMI 1640 medium (Gibco) containing 10% FBS. All the cells were incubated at 37°C in a humidified atmosphere containing 5% CO2. MDA-MB-231 cell lines were treated with 10 nmol/L diABZI (STING agonist; tlrl-diabzi-2, Invivogen) and 1 μg/mL H-151 (STING inhibitor; inh-h151, Invivogen) for 24 hours. No authentication of these cell lines was performed after they were purchased. Cell morphology and growth characteristics were monitored during the study to ensure their authenticity. All cell lines used in experiments were cultured for less than 10 passages. Transient transfection Human breast cancer cells (MDA-MB-231 and BT20) were transiently transfected with siRNA against control (sc-37007), cGAS (sc-95512), and interferon regulatory factor 3 (IRF3; sc-35710), all purchased from Santa Cruz Biotechnology, using Lipofectamine RNAiMAX (Invitrogen). Bioinformatics analysis The expression of PD-L1 in patients with TNBC and the correlation of PD-L1 with cGAS–STING pathway–related proteins were evaluated using RNA sequencing (RNA-seq) analysis with The Breast Cancer Gene Expression Miner v4.9 (BC-GenExMiner v4.9) web online tools (http://bcgenex.ico.unicancer.fr/). BC-GenExMiner v4.9 was used to annotate breast cancer RNA-seq data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus databases (GSE96058 and GSE81538). To analyze the three predicted IRF3-binding sites in the PD-L1 promoter regions, EPD (https://epd.epfl.ch/), PROMO (https://alggen.lsi.upc.es/), and JASPAR (https://jaspar.genereg.net/) datasets were used. Western blot analysis All human (MCF-10A, BT474, SK-BR-3, MCF7, T47D, MDA-MB-231, BT20, and MDA-MB-453) and murine breast (4T1 and EMT6) cell lines were harvested, and proteins were extracted with RIPA buffer (50 mmol/L Tris, 150 nmol/L NaCl, 1% Triton X-100, 0.1% SDS, and 1% Na-deoxycholate; pH 7.4) with protease and phosphatase inhibitor cocktails (P8340 and P5726, Sigma-Aldrich) and then subjected to SDS-PAGE. Proteins were transferred onto a nitrocellulose membrane (GE HealthCare Life Sciences), blocked with TBS containing 0.2% Tween 20% and 5% skim milk, incubated with a primary antibody, and then incubated with a horseradish peroxidase–conjugated secondary antibody. Protein expression was estimated using X-ray films and a chemiluminescence protocol (DoGEN enhanced chemiluminescence; Daeil Lab Service Co. Ltd.). Blots were normalized to β-actin as a loading control and quantified using the ImageJ software (NIH). Information regarding the antibodies used is provided in Supplementary Table S1. qRT-PCR Total RNA was extracted from human breast cancer cell lines (MDA-MB-231 and BT20) using the TRIzol reagent (Life Technologies). The cDNA was amplified from 2 μg RNA using a reverse transcriptase PCR kit (Life Technologies). cDNA was then used as a template to perform qRT-PCR analysis. The PCR reaction mixture was adjusted to 20 μL with 10 μL 2× TaqMan Gene Expression Master Mix (4369016, Thermo Fisher Scientific), 1 μL TaqMan probe, 2 μL cDNA, and 7 μL RNase-free water. qRT-PCR was performed using the QuantStudio 6 Flex system (Applied Biosystems). Three replicates were run for each sample. The cycle threshold values of the target genes were obtained for each sample. The relative expression levels of target mRNAs were quantified via comparative (Ct 2−ΔΔCT) methods. Transcript amplification was conducted using specific gene primers for the TaqMan probes. Gene expression was normalized to GAPDH expression. The TaqMan probes used were as follows: GAPDH (Hs99999905_m1) and PD-L1 (Hs01125301_m1). Measurement of cell surface PD-L1 expression Human (MDA-MB-231 and BT20) and murine breast cancer (4T1 and EMT6) cell lines were trypsinized, washed with cold PBS, and centrifuged at 1,000 revolutions per minute (rpm) for 5 minutes. Cells were resuspended in 200 μL 1× flow cytometry staining buffer (FC001, R&D Systems) and incubated with PE-conjugated antibodies against PD-L1 or isotype control for 30 minutes at room temperature in the dark. The cells were analyzed by flow cytometry (BD LSRFortessa X-20, BD Biosciences). The median fluorescence intensity (MFI) indicates the expression level of PD-L1 on the cell surface. The MFI was quantified using FlowJo software v10.10 (BD Biosciences). The relative MFI was normalized to that of the isotype control. Information about the antibodies used is provided in Supplementary Table S2. Luciferase reporter assay For the luciferase reporter assay, nuclear factor of activated T cells–luciferase reporter transfected Jurkat T cells were purchased from Promega Corporation (J1622) in 2021. MDA-MB-231 (7 × 103 cells/well) and BT20 (1 × 104 cells/well) cells were seeded into white 96-well plates and pretreated with 2.5 μmol/L CBD (Hammer Enterprises) and/or 50 μg/mL atezolizumab (Tecentriq; Roche) for 1 hour. Jurkat T cells were then added to the wells at a ratio of 1:10 of cancer cells to T cells. To stimulate Jurkat T cells, 0.1 μg/mL anti-CD3 (555329, BD Biosciences) and anti-CD28 (555725, BD Biosciences) were added to the coculture system for 24 hours. After 24 hours of coculture, luciferase activity was measured using the Bio-Glo Luciferase Assay System (G7941, Promega) and detected using a luminescence microplate reader (Varioskan LUX, Thermo Fisher Scientific). Anticancer cytokine secretion by the coculture system MDA-MB-231 (1 × 105 cells/well) and BT20 (2 × 105 cells/well) cells were seeded in 24-well plates and pretreated with 2.5 μmol/L CBD and/or 50 μg/mL atezolizumab for 1 hour. These cells were subsequently cocultured with Jurkat T cells or human PBMCs at a ratio of 1:10 of cancer cells to T cells. To stimulate Jurkat T cells and human PBMCs, 0.1 μg/mL anti-CD3 and anti-CD28 were added to the coculture system for 24 hours. Supernatants were collected after 24 hours. Concentrations of IL2 and IFNγ were examined using Human IL2 ELISA Kit (DY202-05, R&D Systems) and human IFNγ ELISA Kit (DY285B-05, R&D Systems), respectively, according to the manufacturer’s instruction. The levels of the secreted cytokines were measured using a microplate reader (Molecular Devices). Human PBMC–mediated tumor killing assay MDA-MB-231 (1 × 105 cells/well) and BT20 (2 × 105 cells/well) cells were seeded in 24-well plates and pretreated with 2.5 μmol/L CBD and/or 50 μg/mL atezolizumab for 1 hour. The cells were subsequently cocultured with human PBMCs at a ratio of 1:10. To stimulate human PBMCs, 0.1 μg/mL anti-CD3 and anti-CD28 were added to the coculture system for 24 hours. After 24 hours of coculture, the cell debris and human PBMCs were removed by washing with PBS. Living cancer cells were subjected to 0.5% crystal violet (C0775, Sigma Aldrich) staining and observed using an inverted microscope (CKX53, Olympus Life Science). The cells were then destained with 10% acetic acid solution for 30 minutes, and the optical density was quantified using a microplate reader at a wavelength of 570 nm. Cell proliferation assay Cell proliferation was measured using a WST-1 assay (EZ-3000, DoGEN). The cells (MDA-MB-231 and BT20) were seeded in 96-well plates. The cells were treated with increasing concentrations of CBD (0, 1, 2.5, and 5 μmol/L) for 24 hours and then added to the WST-1 solution for 4 hours at 37°C. The absorbance was determined at 450 mm using a microplate reader. Extracellular ATP release assay The levels of extracellular ATP were measured using EZ-ATP Assay Kit (DG-ATP100, DoGEN). The cells (MDA-MB-231 and BT20) were seeded in a cell culture plate. The cells were treated with increasing concentrations of CBD (0, 1, 2.5, and 5 μmol/L) for 24 hours. The cells were harvested, and the following operations were performed according to the manufacturer’s instructions. The cells were lysed using 100 μL of ATP assay buffer and immediately subjected to deproteinization. The deproteinized lysate was then added to the reaction mixture. After incubation for 30 minutes at room temperature in the dark, the absorbance was measured at 570 nm using a microplate reader. The absorbance was normalized to the protein concentration. Apoptosis analysis Cell apoptosis was estimated using Annexin V-FITC Apoptosis Detection Kit (LS-02-100; BioBud, Seoul, Korea). The cells (MDA-MB-231 and BT20) were trypsinized and centrifuged at 1,000 rpm for 5 minutes. The cell pellet was resuspended and stained with annexin V-FITC and propidium iodide solution in 1x binding buffer for 30 minutes at room temperature in the dark. The stained cells were evaluated by flow cytometry. Cell death was quantified using FlowJo software. Chromatin immunoprecipitation assay Chromatin immunoprecipitation (ChIP) assays were conducted using a ChIP assay kit (17-295, Millipore Corp.) following the manufacturer’s instructions. Briefly, after fixation with 1% formaldehyde for 10 minutes to cross-link the DNA and proteins, the cells (MDA-MB-231) were harvested using a cell scraper. The pellet was resuspended in SDS lysis buffer containing phenylmethane sulfonyl fluoride and a protease inhibitor (P8340, Sigma Aldrich). The mixture was incubated on ice for 10 minutes. The cells were sonicated to obtain 200 to 1,000 base pair DNA fragments. Immunoprecipitation was performed overnight with either control IgG or IRF3 (#11904, Cell Signaling Technology) primary antibodies. The next day, chromatin complexes were pulled down with protein A/salmon sperm DNA for 1 hour at 4°C. The complexes were thoroughly washed and eluted. Reverse cross-linking was performed at 95°C for 15 minutes. Phenol/chloroform/isoamyl alcohol extraction was used to purify DNA. DNA was amplified by PCR using the gene specific primers listed in Supplementary Table S3. Syngeneic mouse models All animal experiments were performed in accordance with the animal care guidelines approved by the Institutional Animal Care and Use Committee of Korea University College of Medicine (KOREA-2022-0088). Female BALB/c mice, ages 8 weeks (n = 24), were obtained from Orient Bio and housed in a specific pathogen-free environment. 4T1 and EMT6 murine TNBC cells (5 × 105 cells) were implanted into the fourth mammary fat pad. Tumor volumes were monitored until the tumor size reached approximately 100 mm3. Animals were randomized into four drug treatment groups: control (n = 6), CBD (n = 6), anti–PD-L1 (n = 6), and CBD+anti–PD-L1 mAb (n = 6). The mice were intraperitoneally injected with 10 mg/kg CBD every 2 days and/or 5 mg/kg anti–mouse PD-L1 (10F.9G2, Bio X cell) every 3 days. Tumor volumes were measured every 2 days using a digital caliper. Tumor volume was calculated with the following formula: tumor volume (mm3) V = 1/2 × (Length × Width2). The mice were euthanized when the tumor size reached 1,500 mm3. Analysis of PD-L1 expression on tumor tissues Tumor tissues were excised and divided into two parts for histopathologic and flow cytometry analyses. Tumor tissues for flow cytometry were cut into small pieces and digested with 300 U/mL type Ⅳ collagenase (Worthington Biochemical) and 1 mg/mL DNase I (Roche Diagnostics) at 37°C for 2 hours. The cells were then washed with PBS and centrifuged at 1,000 rpm for 10 minutes. The cell pellet was trypsinized and incubated with 5 mg/mL dispase Ⅱ (Gibco) at 37°C for 5 minutes. The cells were then filtered to obtain a single-cell suspension. Red blood cells were removed using red blood cell lysis buffer (Sigma Aldrich). The cells were resuspended in flow cytometry staining buffer and incubated with PE-conjugated antibodies against PD-L1 or isotype control for 30 minutes at room temperature in the dark. Subsequently, the cells were analyzed by flow cytometry, as described in the “Measurement of cell surface PD-L1 expression” section of this article. The results were analyzed using FlowJo software. Information about the antibodies used is provided in Supplementary Table S2. IHC staining IHC staining was conducted to evaluate PD-L1 expression and CD8+ T-cell infiltration into the tumor area. Formalin-fixed paraffin-embedded tissue sections were deparaffinized and dehydrated in xylene and graded ethanol solutions. After deparaffinization and antigen retrieval, tissue slides were incubated with 3% hydrogen peroxide (H2O2)-blocking reagent for 15 minutes and heated at 100°C for 20 minutes. The slides were blocked with blocking buffer (Dako) at room temperature for 1 hour. Primary antibodies were added, and the slides were incubated overnight at 4°C. The next day, the slides were incubated with a horseradish peroxidase–conjugated secondary antibody. The slides were then stained with DAB complex (K3468, Dako) and hematoxylin (S3309, Dako) after dehydration and sealing, respectively. The slides were observed under a microscope (BX43, Olympus Life Science) and evaluated by scanning under high magnification (200× magnification). Information about the antibodies used is provided in Supplementary Table S4. PD-L1 expression was scored based on the staining intensity and percentage of positive cells. The intensity was classified into four scores: “0” for no expression, “1” for weak expression, “2” for moderate expression, and “3” for high expression. The percentage of positive cells was also divided into four scores: “1” for 0% to 5% positive cells, “2” for 6% to 25% positive cells, “3” for 26% to 50% positive cells, “4” for 51% to 75% positive cells, and “5” for 76% to 100% positive cells. These two scores were obtained by multiplying the staining intensity with the percentage of positive cells. These values can range from 0 to 15. Cells staining positive for either CD8 or granzyme B were counted as the number of infiltrating T lymphocytes. The intratumoral area was selected for TIL evaluation. The results were obtained by counting the number of CD8+ cells or granzyme B+ cells in the selected fields. Values are expressed as the number of cells per mm2. Statistical analysis All in vitro experiments were performed independently at least three times. Statistical significance was determined using the GraphPad Prism software v8.0.2. The results were expressed as the mean of arbitrary values ± SD. All results were evaluated using an unpaired Student t test, and a P value of less than 0.05 was considered significant. Each ∗, ∗∗, ∗∗∗ stands for ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗, P < 0.001, respectively. Data availability The data generated in this study are available in the article and its accompanying supplementary files or upon request from the corresponding author. Results CBD upregulates PD-L1 expression in TNBC cells In the initial experiments, we assessed PD-L1 expression in patients with breast cancer based on RNA-seq analysis using the online tool BC-GenExMiner v4.9. We found that the levels of PD-L1 mRNA were higher in patients with TNBC than in those with the other subtypes of breast cancer (Fig. 1A). Further comparison between the TNBC and non-TNBC subtypes revealed a significant difference in the expression of PD-L1 (Fig. 1B). Next, we performed Western blotting to determine PD-L1 protein expression in various human breast cancer cell lines, including TNBC and non-TNBC cells. Protein expression levels of PD-L1, but not PD-L2, were higher in TBNC cell lines than in non-TNBC cell lines (Fig. 1C; Supplementary Fig. S1A). CBD upregulates PD-L1 expression in TNBC cells. A and B, RNA-seq analysis of PD-L1 expression in different breast cancer subtypes. A, TNBC (n = 584), HER2 (n = 343), luminal A (n = 1877), and luminal B (n = 1,617), as well as TNBC and non-TNBC subtypes. B, TNBC (n = 293) and non-TNBC subtypes (n = 3,887). C, Endogenous protein levels of PD-L1 in various breast cancer cell lines and normal breast cell lines were determined by Western blot analysis. β-actin was used as a loading control. D, Human TNBC cell lines (MDA-MB-231 and BT20) were treated with increasing concentrations of CBD (0, 1, 2.5, and 5 μmol/L) for 24 hours. Protein levels of PD-L1 were determined by Western blot analysis. β-actin was used as a loading control. E, MDA-MB-231 and BT20 cells were treated with increasing concentrations of CBD (0, 1, 2.5, and 5 μmol/L) for 24 hours. Relative PD-L1 mRNA expression levels were measured by qRT-PCR. F, Flow cytometry analysis showing the expression of cell surface PD-L1 in TNBC cells. The relative MFI of PD-L1 expression is shown. Data are shown as the mean ± SD and analyzed by unpaired Student t test. **, P < 0.01; ***, P < 0.001. Next, we tested the effect of CBD on PD-L1 expression in the breast cancer cell lines. Human TNBC (MDA-MB-231 and BT20; Fig. 1D) and murine TNBC (4T1 and EMT6) cell lines (Supplementary Fig. S2A) were treated with CBD (0–5 μmol/L). The Western blot results showed that protein levels of PD-L1 were increased by CBD in a dose-dependent manner. Treatment with CBD did not increase PD-L1 expression in PD-L1–negative TNBC cell lines (MDA-MB-453; Supplementary Fig. S1B) or in other cell lines, including HER2-positive (BT474 and SK-BR-3) and hormone receptor–positive (MCF7 and T47D) cell lines (Supplementary Fig. S1C and S1D). Moreover, PD-L2 expression levels did not increase in human TNBC cell lines (Supplementary Fig. S1E). To determine whether upregulation of PD-L1 protein was initiated at the transcriptional level, qRT-PCR was performed. The mRNA level of PD-L1 was increased in human PD-L1+ TNBC cell lines (MDA-MB-231 and BT20) by CBD treatment (Fig. 1E). PD-L1 is located on the surface of tumor cells and is a key immune checkpoint molecule in immunotherapy (7). To assess whether CBD-induced PD-L1 gene transcription could lead to the production of functionally and clinically targetable PD-L1 proteins, we evaluated PD-L1 expression on the cell surface by flow cytometry analysis (Fig. 1F; Supplementary Fig. S2B). CBD treatment resulted in elevated PD-L1 expression on the surface of human (MDA-MB-231 and BT20) and murine (4T1 and EMT6) PD-L1+ TNBC cells. These results demonstrated that CBD induces PD-L1 expression in PD-L1+ TNBC cells. Last, to determine whether CBD affected cell proliferation and apoptosis, TNBC cell lines were treated with 0 to 5 μmol/L CBD and then cell proliferation, apoptosis, and levels of extracellular ATP were measured (Supplementary Fig. S3A–S3D). Combination treatment of CBD and atezolizumab triggers anticancer immunity Upregulation of PD-L1 in tumor cells can lead to reduced cytotoxic T cell–mediated antitumor effects. T-cell activation is a crucial indicator of ICI treatment (8). To investigate whether CBD-mediated PD-L1 upregulation in tumor cells altered immunologic surveillance by T cells, we analyzed T-cell activation using luciferase activity in engineered Jurkat T cells. We determined the effects of atezolizumab on the ability of T cells to suppress TNBC cells. Atezolizumab (0–100 μg/mL) was added to cocultures of MDA-MB-231 or BT20 cells with Jurkat T cells. At a dose of 50 μg/mL, atezolizumab slightly enhanced T-cell activation in the coculture system (Supplementary Fig. S4A). We observed that treatment with CBD significantly reduced Jurkat T-cell activation in the presence of MDA-MB-231 or BT20 cells by increasing PD-L1 expression in the tumor cells (Fig. 2A). In contrast, combination treatment with CBD and atezolizumab increased T-cell activation. These findings suggest the potential clinical utility of combining CBD with ICIs as a therapeutic therapy for TNBC as a result of the ability of CBD to regulate PD-L1 expression in tumor cells. Combination treatment of CBD and atezolizumab triggers anticancer immune response. A, MDA-MB-231 and BT20 cells were preincubated with 2.5 μmol/L CBD and 50 μg/mL atezolizumab for 1 hour and subsequently cocultured with activated Jurkat T cells at a cancer to T-cell ratio of 1:10 in the presence of a stimulator (anti-CD3/CD28) for additional 24 hours. Luciferase activity was measured using a luciferase system and microplate reader. B and C, MDA-MB-231 and BT20 cells were preincubated with 2.5 μmol/L CBD and 50 μg/mL atezolizumab for 1 hour and subsequently cocultured with activated Jurkat T cells or human PBMCs in the presence of a stimulator (anti-CD3/CD28) for additional 24 hours. Levels of IL2 (B) and IFNγ (C) were measured by ELISA assay. D–F, Human PBMC-mediated tumor-killing assay. MDA-MB-231 cells were pretreated with or without 2.5 μmol/L CBD and 50 μg/mL atezolizumab for 1 hour and cocultured with human PBMCs at the indicated effector and target cell ratio of 10:1 (effector: PBMCs; target: TNBC cells) for additional 24 hours. Human PBMCs and cell debris were washed and removed with PBS. Living tumor cells were visualized by crystal violet staining and washed with acetic acid solution. Bar graph representing the proportion of death cells is shown (D). The expression of cleaved (c)-PARP was determined by Western blot analysis (E). β-actin was used as a loading control (F). The proportion of apoptotic cell death in tumor cells was estimated by annexin V/PI staining by flow cytometry analysis. Data are shown as the mean ± SD and analyzed by unpaired Student t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Next, to test the potential synergistic effects of CBD and atezolizumab, TNBC cells were cocultured with Jurkat T cells or human PBMCs, and the quantities of released antitumor cytokines, including IL2 and IFNγ, were assessed (Fig. 2B and C; Supplementary Fig. S4B and S4C). CBD treatment alone significantly suppressed T cell–mediated cytokine secretion. However, combination treatment with CBD and atezolizumab increased the secretion of these cytokines, indicating an increased activation of T cells. Furthermore, to determine whether combination treatment could exert antitumor killing activity through T-cell activation, we investigated the effects of combined therapy with CBD and atezolizumab on human PBMC activation in a coculture system (Fig. 2D). CBD suppressed the tumor-killing effect through PD-L1 upregulation in tumor cells. Combination treatment with CBD and atezolizumab resulted in a significant cytotoxic effect on tumor cells. We then investigated whether immune-mediated antitumor responses could induce immunogenic cell death in tumor cells. The results showed that combination treatment with CBD and atezolizumab elevated apoptotic cell death in tumor cells (Fig. 2E and F). Taken together, these results revealed that CBD treatment alone suppressed T cell–mediated cytokine secretion and tumor killing effects, whereas the combination treatment of CBD and atezolizumab increased the secretion of cytokines and antitumor killing activity through T-cell activation, leading to elevated apoptotic cell death in tumor cells. These findings suggest the potential clinical utility of combining CBD with ICIs to treat patients with PD-L1+ TNBC. CBD promotes PD-L1 upregulation via activation of the cGAS–STING pathway in TNBC cells Next, we investigated the molecular mechanisms underlying CBD induction of PD-L1 expression. We analyzed the correlation coefficient in patients with TNBC to assess the interaction between PD-L1 and the cGAS–STING pathway using RNA-seq analysis. There was a positive correlation between PD-L1 expression and the cGAS–STING pathway in patients with TNBC (Fig. 3A). We further performed Western blot analysis to elucidate whether CBD could activate the cGAS–STING pathway in TNBC cells. The results indicated that the levels of phosphorylated STING, TBK1, and IRF3 increased after CBD treatment (Fig. 3B). In addition, using siRNA to target cGAS, we showed that CBD stimulated the cGAS–STING pathway in TNBC cells in a cGAS-dependent manner (Fig. 3C). Furthermore, treatment of MDA-MB-231 cells with 10 nmol/L diABZI, a STING agonist, increased PD-L1 expression in TNBC cells (Fig. 3D and E). In contrast, when MDA-MB-231 cells were treated with 1 μg/mL H151, a STING inhibitor, the CBD-mediated elevation of PD-L1 was reduced, as shown by decreases in its protein levels (Fig. 3F) and cell surface expression (Fig. 3G), compared with the CBD treatment condition. These findings suggested that the cGAS–STING pathway plays an essential role in mediating CBD-induced PD-L1 expression in TNBC cells. CBD promotes PD-L1 upregulation via activation of the cGAS–STING pathway in TNBC cells. A, Correlation between IRF3 and PD-L1 expression was evaluated by RNA-sequence analysis by BC-GenExMiner v4.9 web online tool. B, Western blot analysis of the cGAS–STING pathway in MDA-MB-231 cells after treatment with CBD. C, MDA-MB-231 cells were transfected with cGAS siRNA. Transfected cells were treated with 2.5 μmol/L CBD for 24 hours. Protein expression was detected by Western blot analysis. β-actin was used as a loading control. D and E, MDA-MB-231 cells were treated with 10 nmol/L dimeric amidobenzimidazole (diABZI) STING agonist for 24 hours. F and G, MDA-MB-231 cells were pretreated with 1 μg/mL H151 STING antagonist for 1 hour. After pretreatment, the cells were treated with 2.5 μmol/L CBD for 24 hours. Protein expression was detected by Western blot analysis (D and F). β-actin was used as a loading control. Expression of cell surface PD-L1 was determined by flow cytometry analysis (E and G). The relative MFI for PD-L1 expression levels is shown. Data are shown as the mean ± SD and analyzed by unpaired Student t test. ***, P < 0.001. IRF3 binds directly to the PD-L1 gene promoter region in TNBC cells IRF3 is a transcription factor essential for the production of type I IFNs. It has been identified downstream of the cGAS–STING pathway (45). To investigate whether IRF3 regulates PD-L1 transcription, a ChIP assay was performed. Bioinformatic tools of the EPD (https://epd.epfl.ch/), PROMO (https://alggen.lsi.upc.es/), and JASPAR (https://jaspar.genereg.net/) databases showed that there were three predicted IRF3 binding sites (BS1: -2033/-2025; BS2: -946/-938, and BS3: -146/-138) in the PD-L1 gene promoter region (Fig. 4A–C). MDA-MB-231 cells were treated with CBD and cross-linked chromatin isolated by immunoprecipitation using a specific anti-IRF3 and IgG control, followed by PCR analysis for DNA enrichment using specific primers. The results revealed that IRF3 was enriched in BS2 of the PD-L1 gene promoter region in MDA-MB-231 cells after CBD treatment (Fig. 4D). In contrast, BS1 and BS3 were not enriched in the promoter region of PD-L1. Taken together, these results indicate that IRF3 can bind directly to the PD-L1 promoter to modulate its transcriptional activation. We further confirmed whether IRF3 regulates PD-L1 mRNA and protein levels (Fig. 4E–G). We found that IRF3 knockdown dramatically reduced PD-L1 expression at both mRNA and protein levels. Taken together, these findings revealed that IRF3 can promote CBD induction of PD-L1 expression in TNBC cells by directly binding to the PD-L1 gene promoter. IRF3 binds directly to the PD-L1 gene promoter region in TNBC cells. A, A schematic representation of the PD-L1 gene promoter region. Three possible IRF3-binding site sequences, named BS1, BS2, and BS3, were indicated in red upstream of transcription start site in the PD-L1 gene. B, Sequence of the PD-L1 promoter region. Three possible IRF3-binding site sequences on the PD-L1 promoter region are shown in red. C, The sequence of the IRF3-binding motif. D, Products of ChIP-PCR in the input, IgG, IRF3, and water (DW) groups were analyzed by agarose gel electrophoresis. PCR was performed with specific primers of IRF3-binding sites. E–G, MDA-MB-231 cells were transfected with control and IRF3 siRNA. Transfected cells were treated with 2.5 μmol/L CBD for 24 hours. The mRNA (E), protein (F), and expression of cell surface PD-L1 (G) were subjected by qRT-PCR, Western blot analysis, and flow cytometry analysis. The relative MFI for PD-L1 expression level is shown. Data are shown as the mean ± SD and analyzed by unpaired Student t test. ***, P < 0.001. Synergistic effect of CBD and anti–PD-L1 mAb in in vivo experiments Based on the results of the in vitro experiments, we evaluated the effect of CBD and anti–PD-L1 in in vivo experiments by monitoring tumor growth and the surrounding TME using syngeneic mouse models (Supplementary Fig. S5A). Before performing in vivo experiments, we used murine TNBC cell lines (4T1 and EMT6) and confirmed that CBD upregulated PD-L1 expression in the cells (Supplementary Fig. S2A and S2B). A syngeneic mouse model was established by subcutaneously implanting murine TNBC cell lines into the mammary fat pads of female BALB/c mice. After observing tumor growth, the mice were treated with vehicle control, 10 mg/kg CBD, 5 mg/kg anti–PD-L1, or a combination of CBD and anti–PD-L1. Treatments were administered via i.p. injection every 2 or 3 days. The tumor size was measured daily for approximately 30 and 20 days. At the end of the study, the mice were sacrificed and tumors were excised. We found that combination treatment with CBD and anti–PD-L1 significantly inhibited tumor growth compared with the control and single-treatment groups (Fig. 5A). The tumor size was significantly smaller in the combination treatment group than in the other groups (Fig. 5B; Supplementary Fig. S5B). The body weight did not show any compelling changes during the treatment period (Supplementary Fig. S5C). Flow cytometry and IHC staining results indicated that tumors treated with CBD alone or a combination of CBD and anti–PD-L1 exhibited marked increases in PD-L1 expression within tumor tissues (Fig. 5C and D; Supplementary Fig. S5D). Moreover, combined treatment significantly triggered the infiltration of CD8+ T cells into the tumor area, accompanied by increased granzyme B expression (Fig. 5E and F). These findings strongly suggest that combined treatment with CBD and anti–PD-L1 might effectively promote antitumor immunity and prime a favorable TME for cancer immunotherapy. Synergistic effect of CBD and anti–PD-L1 in in vivo experiments. A, The tumor volume of each group was measured every 2 days (n = 6). B, Tumor images were determined after the mice were sacrificed. C, Flow cytometry analysis was performed to estimate PD-L1 expression in tumor cells from each group (n = 6). The relative MFI of PD-L1 expression is shown. D–F, IHC staining of PD-L1 (D), CD8+ T cells (E), and granzyme B (F) in tumor sections from each group. Quantifications of each group (n = 6). Data are shown as the mean ± SD and analyzed by unpaired Student t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Discussion TNBC remains a very difficult illness to treat because of immune evasion, metastasis, and a lack of efficient targeted treatments (2). Recently, the use of ICIs with chemotherapy has shown therapeutic benefits in patients with PD-L1+ TNBC. These clinical outcomes prompted the original expedited approval of this treatment. Despite the fact that this innovative therapy has become a treatment option for patients with TNBC with PD-L1 expression, it has a low response rate, acquired resistance to ICIs, lack of biomarkers, necessitating the development of novel strategies to improve immunotherapy efficacy (18). The TME is closely related to prognosis and response to ICIs. Levels of TILs, PD-L1 expression, and cytokine production might be used to characterize the TME as either hot (immunogenic) or cold (nonimmunogenic; ref. 47). In general, hot tumors respond better to ICIs, such as anti–PD-1/PD-L1. As a result, several studies have attempted to increase the responsiveness of cold tumors to immunotherapy. The following constitute a few of the aspects that may explain why most combination therapies with anti–PD-1/PD-L1 would produce stronger clinical evidence: (i) a hot tumor will be targeted, for example, by increasing PD-L1 expression or TILs, which can enhance the antitumor activity of an anti–PD-1/PD-L1; (ii) focusing on other immune cells, such as NK cells, macrophages, and Treg cells, in the TME offers an appreciable effect; and (iii) reducing the dosage or treatment duration compared with a single treatment might reduce pharmaceutical adverse effects. To improve the efficiency of ICIs, we focused on controlling PD-L1 expression in tumor cells. Much research on CBD has focused on the mechanisms of cell death in cancer. Studies have shown that CBD can effectively inhibit proliferation and induce apoptosis of cancer cells in both in vitro and in vivo experiments. CBD induced apoptosis and autophagy in CBD-treated MDA-MB-231 breast cancer cells by inhibiting the AKT and mTOR signaling pathways (23). Our previous studies have revealed that CBD can promote apoptotic cell death by reducing XIAP protein while increasing ubiquitination of XIAP and stimulating mitochondrial dysfunction in gastric cancer cells (29). CBD has been demonstrated to be able to suppress angiogenesis and stemness in breast cancer cells via the HIF-1α pathway (31). In this study, we found that CBD treatment inhibited proliferation and induced extracellular ATP release, which is an indicator of immunogenic cell death in breast cancer cell lines. In syngeneic mouse experiments using 4T1 and EMT6 murine TNBC cells, treatment with CBD alone reduced tumor burden compared with the control. Moreover, CBD-mediated immunogenic cell death in cancer cells can efficiently recruit immune cells into tumor tissues, activate antigen-presenting cells [dendritic cells (DC)], and induce robust intratumoral and systemic antitumor immune stimulations. In this regard, further studies should address the mechanism of CBD-mediated immunogenic cell death in cancer cells and activation of DCs. Recent studies have investigated the effects of simultaneous ICI treatment and cannabis in vivo. CBD significantly decreased the number of protumor macrophages and increased the number of antitumor macrophages in tumors. CBD-mediated macrophage changes enhanced the response to anti–PD-1 immunotherapy in xenograft mouse models (38). CBD, which is a TRPV2 agonist, confirmed its therapeutic potential in non–small cell lung cancer cells by significantly increasing intracellular Ca2+ levels in cytokine-induced killer cells (43). In contrast, studies have reported that both cannabis-derived and endogenous cannabinoids impair T cell–mediated antitumor immunity by inhibiting the JAK1–STAT signaling pathway in T cells through CB2 (44). Moreover, some retrospective clinical studies have suggested a deleterious effect of cannabis on ICI treatment outcomes (39–41). Despite its effects on tumor cells, it is unclear whether CBD inhibits tumor progression through TME regulation. Our study provided new insights indicating that CBD exerts immunogenic cell death effects and modulates immune-related responses, at least in part, by modulating immune checkpoint molecules in TNBC cells. We found that CBD induced PD-L1 expression in TNBC cells. In contrast, PD-L2 expression did not change in the CBD-treated TNBC cell lines. PD-L2, another immune checkpoint molecule located on the surface of tumor cells, is not yet fully understood in terms of its interaction with immune cells. Furthermore, CBD synergized with anti–PD-L1 to enhance T cell–mediated tumor-killing activity and inhibit tumor growth both in vitro and in vivo. Data from TNBC cells cocultured with T cells showed that CBD suppressed T-cell capacity to produce anticancer cytokines due to PD-L1 upregulation in tumor cells, whereas levels of cytokines could be restored or even increased by combination treatment with CBD and atezolizumab. The cGAS–STING pathway is a crucial component of the innate immune system that senses cytosolic DNA and activates type I IFN production, which in turn stimulates adaptive immune responses against tumors (45). Moreover, the STING signaling pathway initiates an inflammatory response driven by type I IFN, which promotes DC activation and cross-presentation of tumor antigens for subsequent T-cell priming (46). In addition to T cells, the STING signaling pathway might be activated in macrophages, B cells, and other leukocytes to create type I IFNs (48). Moreover, NK cells activated by the STING pathway are geared up for eliminating tumor cells (49). These findings suggest that the STING signaling pathway is crucial for several innate and adaptive immune responses that can be used to treat cancer. The potential of STING agonists as cancer treatments to trigger antitumor immune responses was revealed by insights into the roles of STING in immune modulation. In this study, we identified a significant positive correlation between PD-L1 expression and the cGAS–STING pathway in patients with TNBC. This provides a mechanism for CBD in PD-L1 upregulation via activation of the cGAS–STING pathway in TNBC cells. One of the most noteworthy outcomes of this study was that IRF3 could directly bind to the PD-L1 gene promoter region and induce PD-L1 expression in response to CBD treatment. Our knowledge of the function of the STING pathway in immunotherapy and PD-L1 expression has been improved by these findings, which points to a potential mechanism for improved antitumor immunity when the STING pathway is targeted in TNBC. In summary, our present study showed that CBD had a beneficial effect on PD-L1 induction and that combining CBD with atezolizumab could improve treatment outcomes for patients with PD-L1+ TNBC. Nevertheless, this study did not thoroughly investigate the potential interaction of CBD-affected tumor cells with other immune cells, such as regulatory T cells, NK cells, B cells, and macrophages, in the TME. Further research is needed to elucidate the underlying mechanisms of the correlation with immune cells and to determine the optimal dosage, duration, drug delivery systems, and safety for clinical trials on the efficacy of CBD with ICIs for patients with cancer. Supplementary Material CBD regulates immune checkpoint molecules in breast cancer cell lines CBD-induced PD-L1 expression in murine TNBC cells CBD induced immunogenic cell death in TNBC cells The combination of CBD and atezolizumab stimulated an anti-cancer immune response in a co-culture system Synergistic effects of CBD and anti-PD-L1 mAb in vivo experiments Antibodies for western blot analysis Antibodies for cell surface PD-L1 measurement Primer sequence for ChIP-PCR assay Antibodies for IHC staining